 |
Life Technologies (India) Pvt Ltd. 306, Agarwal City Mall, opposite M2K Pitampura, Delhi-110034 (India) Tel # +91-11-4220-8000; 4220-8111; 4220-8222 Fax# +91-11-4220-8444, Mobile# +91-98105-21400 Email# customerservice@lifetechindia.com |
Liver Diseases
As a complex and vital organ responsible for metabolism and detoxification, the liver is particularly susceptible to toxicity caused by various chemicals, including drugs. Drug-Induced Liver Injury (DILI) is a major cause of drug failures in development. Hepatotoxicity refers to liver damage caused by chemicals, either directly by the drug itself or indirectly through the generation of reactive metabolites. In vitro cell-based toxicity assays offer a valuable approach to mimic in vivo tissue studies and provide a reliable tool for safety evaluation in the early stages of drug discovery. Life Technologies recognizes the importance of assessing drug hepatotoxicity potential during the preclinical stage.
We Offer-
- Innovative efficacy assays on Hepatology
- Test the safety of your drugs or active molecule products in preclinical researches
- Customized services for special requirements on efficacy or safety tests
Life Technologies has developed multiplexed hepatotoxicity assays utilizing various in vitro hepatology models, including primary hepatocytes, HepG2 cell lines, and 3D hepatic models. These models are valuable tools for predicting Drug-Induced Liver Injury (DILI). Our experienced scientists are dedicated to assisting you in achieving your objectives and providing support for your projects.
- Life Technologies provides various 2D culture models, including HepG2 cell line, human primary hepatocytes, and iPSC-derived hepatocytes, for investigating potential adverse hepatotoxicity.
- Life Technologies offers 3D hepatotoxicity screening models derived from hepatocytes of various species.
Life Technologies is committed to delivering highly reliable data on drug hepatotoxicity. With our state-of-the-art infrastructure and expert team, we offer comprehensive preclinical research services to assess the safety of drugs and active molecule products. Our customized solutions are designed to meet your specific needs, ensuring enhanced efficacy and safety measures.
Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
Discovery Services:
- Life Technologies assists in establishing NASH conditions by modulating glucose, fructose, free fatty acids, and lipopolysaccharide (LPS) levels.
- Cytotoxicity assays
- Cytokines analysis: IL-6, TNF-α, MIP-1α (CCL3), MCP-1, IP-10 (CXCL10), IL-8 (CXCL8)
- Expression of profibrotic markers
- Apoptosis marker studies
- Oxidative stress marker studies
- Mitochondrial dysfunction studies
- Cellular lipids and phospholipids estimation by LipidTox staining
Available Models:
- Life Technologies provides human liver microtissues comprising primary human hepatocytes (PHHs), liver endothelial cells (LECs), Kupffer cells (KCs), and hepatic stellate cells (HSCs) in physiologically relevant ratios.
- 2D and 3D cultures of HepG2, HuH 7, and HepaRG cells
- 3D Hepatospheres of human iPSCs
Techniques Used: Flow Cytometry, Confocal/Fluorescence Microscopy (Multi-colour Immunofluorescence), ELISA (Fluorimetry/Colorimetry), RTqPCR, WB.